CD4 count and viral load time-courses in patients treated with highly active antiretroviral therapy and association with the CDC staging system

HIV Medicine

Volumn 7, Issue 8, 2006, Pages 504-513

  Collazos, J ^a   Knobel, H ^b   Casado, J L ^c  

^a HOSPITAL DE GALDAKAO   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

CD4 lymphocytes; CDC staging system; Highly active antiretroviral therapy; Outcome; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; NELFINAVIR;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL OBSERVATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; QUESTIONNAIRE; TIME; VIROLOGY; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; NELFINAVIR; PROSPECTIVE STUDIES; SPAIN; UNITED STATES; VIRAL LOAD;

EID: 33750973083     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2006.00405.x     Document Type: Article

References (38)

1. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morb Mortal Wkly Rep 1992; 41: 1-19.
2. Kaufmann GR, Bloch M, Finlayson R, Zaunders J, Smith D, Cooper DA. The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy. AIDS 2002; 16: 359-367.
3. Phillips AN, Staszewski S, Weber R et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. J Am Med Assoc 2001; 286: 2560-2567.
4. Cozzi Lepri A, Phillips AN, d'Arminio Monforte A et al. When to start highly active antiretroviral therapy in chronically HIV-infected patients: Evidence from the ICONA study. AIDS 2001; 15: 983-990.
5. Meibohm A, Alexander J Jr, Robertson M et al. Early versus late initiation of indinavir (IDV) in combination with zidovudine (ZDV) and lamivudine (3TC) in HIV-1-infected adults. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, January -February 2000 [Abstract 521].
6. Grabar S, Pradier C, Le Corfec E et al. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS 2000; 14: 141-149.
7. Paredes R, Mocroft A, Kirk O et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: Results from the EuroSIDA study. Arch Intern Med 2000; 160: 1123-1132.
8. Miller V, Staszewski S, Sabin C et al. CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load. J Infect Dis 1999; 180: 530-533.
9. Deeks SG, Hecht FM, Swanson M et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy. AIDS 1999; 13: F35-F43.
10. Kaufmann GR, Perrin L, Pantaleo G et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years. The Swiss HIV Cohort Study. Arch Intern Med 2003; 163: 2187-2195.
11. Knobel H, Alonso J, Casado JL et al. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: The GEEMA study. AIDS 2002; 16: 605-613.
12. Diggle PJ, Liang KY, Zeger SL. The Analysis of Longitudinal Data. Oxford, UK: Oxford University Press, 1994.
13. SAS Institute. SAS/STAT Software: Changes and Enhancements through Release 6.11. Cary, NC: SAS Institute Inc., 1996.
14. Autran B, Carcelain G, Li TS et al. Positive effects of combined antiretroviral therapy on CD4+T cell homeostasis and function in advanced HIV disease. Science 1997; 277: 112-116.
15. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996; 173: 321-329.
16. Pakker NG, Notermans DW, de Boer RJ et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation. Nature Med 1998; 4: 208-214.
17. Kostense S, Raaphorst FM, Notermans DW et al. Diversity of the T-cell receptor BV repertoire in HIV-1-infected patients reflects the biphasic CD4+T-cell repopulation kinetics during highly active antiretroviral therapy. AIDS 1998; 12: F235-F240.
18. Bucy RP, Hockett RD, Derdeyn CA et al. Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest 1999; 103: 1391-1398.
19. Lederman MM, Valdez H. Immune restoration with antiretroviral therapies: implications for clinical management. J Am Med Assoc 2000; 284: 223-228.
20. Le Moing V, Thiebaut R, Chene G et al. Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen. J Infect Dis 2002; 185: 471-480.
21. Viard JP, Mocroft A, Chiesi A et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: Evidence from the EuroSIDA study. J Infect Dis 2001; 183: 1290-1294.
22. Staszewski S, Miller V, Sabin C et al. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. AIDS 1999; 13: 951-956.
23. Staszewski S, Morales-Ramirez J, Tashima KT et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999; 341: 1865-1873.
24. Walmsley S, Bernstein B, King M et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346: 2039-2046.
25. Yamashita TE, Phair JP, Munoz A et al. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS 2001; 15: 735-746.
26. Cohen Stuart JW, Slieker WA, Rijkers GT et al. Early recovery of CD4+T lymphocytes in children on highly active antiretroviral therapy. AIDS 1998; 12: 2155-2159.
27. Teixeira L, Valdez H, McCune JM et al. Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS 2001; 15: 1749-1756.
28. Smith KY, Valdez H, Landay A et al. Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy. J Infect Dis 2000; 181: 141-147.
29. Lee LM, Karon JM, Selick R, Neal JJ, Fleming PL. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-97. J Am Med Assoc 2001; 285: 1308-1315.
30. Mocroft A, Gill MJ, Davidson W, Phillips AN. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. AIDS 1998; 12: 2161-2167.
31. Cozzi Lepri A, Miller V, Phillips AN, Rabenau H, Sabin CA, Staszewski S. The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-therapy viral load and the weeks 4-8 viral load. AIDS 2001; 15: 47-54.
32. Ledergerber B, Egger M, Opravil M et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Lancet 1999; 353: 863-868.
33. The AVANTI Study Group. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients. AIDS 2000; 14: 367-374.
34. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131: 81-87.
35. Casado JL, Perez-Elias MJ, Antela A et al. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. AIDS 1998; 12: F131-F135.
36. Mocroft A, Devereux H, Kinloch-de-Loes S et al. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. AIDS 2000; 14: 1545-1552.
37. Schuurman R, Descamps D, Weverling GJ et al. Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 1996; 34: 3016-3022.
38. Egger M, May M, Chêne G et al. Prognosis of HIV-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet 2002; 360: 119-129.